EXEL catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 15, 2026Sponsor estimate | NCT05678673Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaExelixis · Non-Clear Cell Renal Cell Carcinoma | EXELLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Dec 20, 2026Sponsor estimate | NCT04413123Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCBradley A. McGregor, MD · Papillary Renal Cell Carcinoma | BMYCollaboratorEXELCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT04919122Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaDuke University · Metastatic Renal Cell Carcinoma | EXELCollaboratorBMYCollaboratorPFECollaboratorMRKCollaborator | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT05678673Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaExelixis · Non-Clear Cell Renal Cell CarcinomaActive, not recruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2026Sponsor estimatePhase 2NCT04413123Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCBradley A. McGregor, MD · Papillary Renal Cell CarcinomaActive, not recruitingBMYCollaboratorEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT04919122Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaDuke University · Metastatic Renal Cell CarcinomaActive, not recruitingEXELCollaboratorBMYCollaboratorPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaWashington University School of Medicine · Metastatic Soft-tissue Sarcoma | BMYCollaboratorEXELCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaWashington University School of Medicine · Metastatic Soft-tissue SarcomaActive, not recruitingBMYCollaboratorEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.